COMP <GO>
SUPN vs LLY // EV/EBITDA & P/E VALUATION
Supernus Pharmaceuticals Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: SUPN 4
— LLY 10
■ METRIC PARITY
LAST: $41.92 (+0.19%) • MKT CAP: $2.43B
valuation
—
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
valuation
36.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SUPN VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SUPN | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 89.60% | 83.64% | +5.96 | SUPN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -4.50% | 32.36% | -36.86 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.89% | 2.30% | -0.41 | LLY | /fcf-yield <GO> |
| Operating Margin | -8.70% | 40.21% | -48.91 | LLY | /operating-margins <GO> |
| Net Profit Margin | -5.40% | 31.90% | -37.30 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 8.60% | 45.51% | -36.91 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.84 | 9.29 | -4.45 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 6.77% | -0.27 | SUPN | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.0 | 77.9 | -26.89 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 0.51 | +0.37 | SUPN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.0x | 26.3x | -4.25 | SUPN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.43B | $1.33T | -$1.33T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SUPN REV | LLY REV | SUPN GROSS % | LLY GROSS % | SUPN FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $719.0M | $65.18B | 89.6% | 83.0% | $46.0M | $16.81B |
| FY 2024 | $661.8M | $45.04B | 88.2% | 81.3% | $171.2M | $8.82B |
| FY 2023 | $607.5M | $34.12B | 44.0% | 79.3% | $83.7M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SUPN // BETA 0.88
LLY // BETA 0.51